Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)

International Journal of Antimicrobial Agents

Volumn 38, Issue 1, 2011, Pages 65-69

  Pfaller, Michael A ^a,b   Messer, Shawn A ^a   Moet, Gary J ^a   Jones, Ronald N ^a,c   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azoles; Bloodstream infections; Candida; Candidaemia; Echinocandins; Intensive Care Unit

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; FUNGUS IDENTIFICATION; HEALTH PROGRAM; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES COMPARISON; SPECIES DISTRIBUTION;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HOSPITALS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; SPECIES SPECIFICITY; WORLD HEALTH;

EID: 79958066469     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.02.016     Document Type: Article

References (52)

1. D. Armstrong-James Invasive Candida species infection: the importance of adequate empirical antifungal therapy J Antimicrob Chemother 60 2007 459 460 (Pubitemid 47299857)
2. A. Corona, F. Cislaghi, and M. Singer Timely selection of adequate antifungal therapy for candidemia in the critically ill: don't let the yeast rise! Crit Care Med 36 2008 3097 3098
3. J. Morgan Global trends in candidemia: review of reports from 1995-2005 Curr Infect Dis Rep 7 2005 429 439 (Pubitemid 41671586)
4. M.D. Parkins, D.M. Sabuda, S. Elsayed, and K.B. Laupland Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections J Antimicrob Chemother 60 2007 613 618 (Pubitemid 47299877)
5. M.A. Pfaller, D.J. Diekema, R.N. Jones, H.S. Sader, A.C. Fluit, and R.J. Hollis International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program J Clin Microbiol 39 2001 3254 3259 (Pubitemid 32830323)
6. M.A. Pfaller, D.J. Diekema, J.H. Rex, A. Espinel-Ingroff, E.M. Johnson, and D. Andes Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints J Clin Microbiol 44 2006 819 826
7. H.M. Arnold, S.T. Micek, A.F. Shorr, M.D. Zilberberg, A.J. Labelle, and S. Kothari Hospital resource utilization and costs of inappropriate treatment of candidemia Pharmacotherapy 30 2010 361 368
8. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, and R.S. Turpin Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 2006 25 31 (Pubitemid 43939072)
9. K.W. Garey, R.S. Turpin, D.T. Bearden, M.P. Pai, and K.J. Suda Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study Int J Antimicrob Agents 29 2007 557 562 (Pubitemid 46560362)
10. D.I. Hsu, M. Nguyen, L. Nguyen, A. Law, and A. Wong-Beringer A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients J Antimicrob Chemother 65 2010 1765 1770
11. A.J. Labelle, S.T. Micek, N. Roubinian, and M.H. Kollef Treatment-related risk factors for hospital mortality in Candida bloodstream infections Crit Care Med 36 2008 2967 2972
12. M. Morrell, V.J. Fraser, and M.H. Kollef Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Antimicrob Agents Chemother 49 2005 3640 3645 (Pubitemid 41233011)
13. M.D. Zilberberg, M.H. Kollef, H. Arnold, A. Labelle, S.T. Micek, and S. Kothari Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study BMC Infect Dis 10 2010 150
14. B. Almirante, D. Rodríguez, B.J. Park, M. Cuenca-Estrella, A.M. Planes, and M. Almela Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003 J Clin Microbiol 43 2005 1829 1835
15. M. Bassetti, E. Righi, A. Costa, R. Fasce, M.P. Molinari, and R. Rosso Epidemiological trends in nosocomial candidemia in intensive care BMC Infect Dis 6 2006 21
16. P. Eggimann, J. Garbino, and D. Pittet Epidemiology of Candida species infections in critically ill non-immunosuppressed patients Lancet Infect Dis 3 2003 685 702 (Pubitemid 37345347)
17. M. Leone, J. Albanse, F. Antonini, A. Michel-Nguyen, M.C. Blanc-Bimar, and C. Martin Long-term epidemiological survey of Candida species: comparison of isolates found in an intensive care unit and in conventional wards J Hosp Infect 55 2003 169 174 (Pubitemid 37554905)
18. O. Leroy, J.P. Gangneux, P. Montravers, J.P. Mira, F. Gouin, and J.P. Sollet Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006) Crit Care Med 37 2009 1612 1618
19. P.A. Lipsett Surgical critical care: fungal infections in surgical patients Crit Care Med 34 9 Suppl. 2006 S215 S224
20. M. Mean, O. Marchetti, and T. Calandra Bench-to-bedside review: Candida infections in the intensive care unit Crit Care 12 2008 204
21. E.G. Playford, G.R. Nimmo, M. Tilse, and T.C. Sorrell Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008 J Hosp Infect 76 2010 46 51
22. G.H. Xie, X.M. Fang, Q. Fang, X.M. Wu, Y.H. Jin, and J.L. Wang Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients Crit Care 12 2008 R5
23. M.D. Zilberberg, S. Kothari, and A.F. Shorr Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation Crit Care 13 2009 R94
24. M.D. Zilberberg, and A.F. Shorr Fungal infections in the ICU Infect Dis Clin North Am 23 2009 625 642
25. M.A. Pfaller, and D.J. Diekema Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility J Clin Microbiol 40 2002 3551 3557
26. G. Dimopoulos, A. Velegraki, and M.E. Falagas A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece Antimicrob Agents Chemother 53 2009 1242 1244
27. S.K. Fridkin Increasing prevalence of antimicrobial resistance in intensive care units Crit Care Med 29 4 Suppl. 2001 N64 N68
28. S.K. Fridkin, C.D. Steward, J.R. Edwards, E.R. Pryor, J.E. McGowan Jr., and L.K. Archibald Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals Clin Infect Dis 29 1999 245 252 (Pubitemid 29380178)
29. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554 (Pubitemid 36437931)
30. H. Wisplinghoff, T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317 (Pubitemid 39050477)
31. M.A. Pfaller, D. Andes, D.J. Diekema, A. Espinel-Ingroff, D. Sheehan CLSI Subcommittee for Antifungal Susceptibility Testing Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods Drug Resist Updat 13 2010 180 195
32. M.A. Pfaller, D.J. Diekema, D. Andes, M.C. Arendrup, S.D. Brown, and S.R. Lockhart Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria Drug Resist Updat 2011 10.1016/j.drup.2011.01.004 [Epub ahead of print]
33. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Document M27-A3. Wayne, PA: CLSI; 2008.
34. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Document M27-S3. Wayne, PA: CLSI; 2008.
35. M.A. Pfaller, G.J. Moet, S.A. Messer, R.N. Jones, and M. Castanheira Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) J Clin Microbiol 49 2011 396 399
36. M.A. Pfaller, S.A. Messer, L. Boyken, S. Tendolkar, R.J. Hollis, and D.J. Diekema Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program J Clin Microbiol 46 2008 551 559 (Pubitemid 351231301)
37. W.E. Trick, S.K. Fridkin, J.R. Edwards, R.A. Hajjeh, R.P. Gaynes National Nosocomial Infections Surveillance System Hospitals Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999 Clin Infect Dis 35 2002 627 630
38. S.K. Fridkin, D. Kaufman, J.R. Edwards, S. Shetty, and T. Horan Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004 Pediatrics 117 2006 1680 1687 (Pubitemid 46071397)
39. R.A. Hajjeh, A.N. Sofair, L.H. Harrison, G.M. Lyon, B.A. Arthington-Skaggs, and S.A. Mirza Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program J Clin Microbiol 42 2004 1519 1527 (Pubitemid 38500790)
40. M.H. Kollef, L.M. Napolitano, J.S. Solomkin, R.G. Wunderink, I.G. Bae, and V.G. Fowler Health care-associated infection (HAI): a critical appraisal of the emerging threat - Proceedings of the HAI Summit Clin Infect Dis 47 Suppl. 2 2008 S55 S99 quiz S100-1
41. A.N. Sofair, G.M. Lyon, S. Huie-White, E. Reiss, L.H. Harrison, and L.T. Sanza Epidemiology of community-onset candidemia in Connecticut and Maryland Clin Infect Dis 43 2006 32 39 (Pubitemid 43939073)
42. J.D. Sobel Changing epidemiology of invasive candidiasis in intensive care units - much ado about nothing? Crit Care Med 36 2008 2188 2189
43. J.D. Sobel Changing trends in the epidemiology of Candida blood stream infections: a matter for concern? Crit Care Med 38 2010 990 992
44. S. Chandwani, C. Wentworth, T.A. Burke, and T.F. Patterson Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice Curr Med Res Opin 25 2009 385 393
45. Y. Cohen, P. Karoubi, C. Adrie, R. Gauzit, T. Marsepoil, and D. Zarka Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients Crit Care Med 38 2010 826 830
46. D.A. Oxman, J.K. Chow, G. Frendl, S. Hadley, S. Hershkovitz, and P. Ireland Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 65 2010 1460 1465
47. H.Y. Sun, and N. Singh Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review Int J Antimicrob Agents 35 2010 211 218
48. C.D. Pfeiffer, G. Garcia-Effron, A.K. Zaas, J.R. Perfect, D.S. Perlin, and B.D. Alexander Breakthrough invasive candidiasis on micafungin J Clin Microbiol 48 2010 2373 2380
49. F. Chapeland-Leclerc, C. Hennequin, N. Papon, T. Noël, A. Girard, and G. Socié Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient Antimicrob Agents Chemother 54 2010 1360 1362
50. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr., T.F. Calandra, and J.E. Edwards Jr. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
51. N. Kabbara, C. Lacroix, R. Peffault de Latour, G. Socié, M. Ghannoum, and P. Ribaud Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy Haematologica 93 2008 639 640 (Pubitemid 351536400)
52. N.V. Sipsas, R.E. Lewis, J. Tarrand, R. Hachem, K.V. Rolston, and I.I. Raad Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection Cancer 115 2009 4745 4752